Somatic instability of the C9orf72 repeat expansion in blood differs between patients with amyotrophic lateral sclerosis or frontotemporal dementia
Preprint
Abstract
Individuals carrying a G4C2 repeat expansion in C9orf72 can develop amyotrophic lateral sclerosis (ALS) and/or frontotemporal dementia (FTD), at various and unpredictable ages. The contribution of the expansion to this extreme clinical variability remained a matter of debate. In this work, we validated the use of optical genome mapping to efficiently size this expansion from blood and applied this method to a cohort of 54 repeat expansion carriers including patients with FTD (n = 23), ALS (n = 22) and presymptomatic individuals (n = 9). Despite the high variability in expansion profiles, distinct groups can be inferred. Although consensus repeat profiles were similar between FTD and ALS patients, relationships between repeat number, indexes of repeat instability, and the age at sampling differed between clinical conditions. An age at sampling-dependent increase of repeat instability in blood was observed in presymptomatic carriers and FTD patients (p = 0.01 and p = 0.04 respectively), in contrast to patients with ALS (p = 0.9). The proportion of shorter repeats ([500-1500 repeats]) increased with the age at sampling in ALS patients but decreased in presymptomatic and FTD cohorts, while the proportion of larger repeats (>2000 G4C2), in particular those exceeding 4000 repeats, increased along with the age at sampling in presymptomatic carriers and FTD cases (p −e4 and p = 0.006 respectively) conversely to patients with ALS (p = 0.98). In conclusion, this work strongly supports different dynamics of repeat instability of the C9orf72 pathogenic expansion in blood linked to the clinical evolution. These findings provide new insights into the relationship between expansion profiles and clinical variability.Keywords
Funding Information
- Programme Hospitalier de Recherche Clinique
- Pfizer [Innovative Target Exploration Network (ITEN) program]
- ANR Investissements d’Avenir (ANR-10- IAIHU-0006)
- Fondation pour la Recherche sur Alzheimer
- France-DFT
- Region Ile France (SESAME 2019)
- EU Joint Programme - Neurodegenerative Disease Research (01ED2203)
- NIH (P30-AG-072979)
- NIH (P01-AG-066597)
This publication has 24 references indexed in Scilit:
- Long somatic DNA-repeat expansion drives neurodegeneration in Huntington’s diseaseCell, 2025
- Relations between C9orf72 expansion size in blood, age at onset, age at collection and transmission across generations in patients and presymptomatic carriersNeurobiology of Aging, 2019
- DNA methylation age-acceleration is associated with disease duration and age at onset in C9orf72 patientsActa Neuropathologica, 2017
- The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoterMolecular Psychiatry, 2015
- Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degenerationActa Neuropathologica, 2015
- Hypermethylation of repeat expanded C9orf72 is a clinical and molecular disease modifierActa Neuropathologica, 2014
- Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort studyThe Lancet Neurology, 2013
- Large C9orf72 Hexanucleotide Repeat Expansions Are Seen in Multiple Neurodegenerative Syndromes and Are More Frequent Than Expected in the UK PopulationThe American Journal of Human Genetics, 2013
- Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALSNeuron, 2011
- A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTDNeuron, 2011